SIVA1 anticorps (N-Term)
Aperçu rapide pour SIVA1 anticorps (N-Term) (ABIN1450104)
Antigène
Voir toutes SIVA1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Réactivité croisée (Details)
- Species reactivity (tested):Human, Mouse.
-
Purification
- Affinity chromatography purified via peptide column
-
Immunogène
- 16 amino acid synthetic peptide near the amino terminus of human SIVA
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- SIVA1 (SIVA1, Apoptosis-Inducing Factor (SIVA1))
-
Autre désignation
- SIVA1 / SIVA
-
Sujet
- SIVA plays an important role in the apoptotic pathway induced by the CD27 antigen, a member of the tumor necrosis factor receptor (TFNR) superfamily. SIVA is a small cysteine-rich protein with a unique N-terminal amphipathic helical region, a death domain homology region (DDHR) and a C-terminal cysteine-rich B-box-like or zinc-finger-like structure. The DDHR domain binds to CD27 and induces apoptosis in T cells through a caspase-dependent mitochondrial pathway. SIVA inhibits BCL2L1 isoform Bcl-xL anti-apoptotic activity and inhibits activation of NFk-B and promotes T-cell receptor-mediated apoptosis. SIVA represents a potential therapeutic target for the treatment of neuronal cell death diseases.Synonyms: Apoptosis regulatory protein Siva, CD27-binding protein, CD27BP
-
ID gène
- 10572
-
NCBI Accession
- NP_068355
-
Pathways
- Positive Regulation of Endopeptidase Activity
Antigène
-